These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20685117)

  • 41. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
    Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
    J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.
    Zhao XZ; Smith SJ; Métifiot M; Marchand C; Boyer PL; Pommier Y; Hughes SH; Burke TR
    J Med Chem; 2014 Jun; 57(12):5190-202. PubMed ID: 24901667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
    Dayam R; Sanchez T; Neamati N
    ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
    Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
    Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.
    Dewdney TG; Wang Y; Kovari IA; Reiter SJ; Kovari LC
    J Struct Biol; 2013 Nov; 184(2):245-50. PubMed ID: 23891838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.
    Ramkumar K; Tambov KV; Gundla R; Manaev AV; Yarovenko V; Traven VF; Neamati N
    Bioorg Med Chem; 2008 Oct; 16(19):8988-98. PubMed ID: 18805696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
    Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester.
    Wang P; Liu C; Sanches T; Zhong Y; Liu B; Xiong J; Neamati N; Zhao G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4574-8. PubMed ID: 19625188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
    Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
    ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase.
    Zhang D; Debnath B; Yu S; Sanchez TW; Christ F; Liu Y; Debyser Z; Neamati N; Zhao G
    Bioorg Med Chem; 2014 Oct; 22(19):5446-53. PubMed ID: 25150089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors.
    Pace P; Spieser SA; Summa V
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3865-9. PubMed ID: 18595690
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase.
    Chen Q; Cheng X; Wei D; Xu Q
    Interdiscip Sci; 2014 Nov; ():. PubMed ID: 25373632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.
    Fisher TE; Kim B; Staas DD; Lyle TA; Young SD; Vacca JP; Zrada MM; Hazuda DJ; Felock PJ; Schleif WA; Gabryelski LJ; Anari MR; Kochansky CJ; Wai JS
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6511-5. PubMed ID: 17931865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.
    Neamati N; Hong H; Owen JM; Sunder S; Winslow HE; Christensen JL; Zhao H; Burke TR; Milne GW; Pommier Y
    J Med Chem; 1998 Aug; 41(17):3202-9. PubMed ID: 9703465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of substitution on novel tricyclic HIV-1 integrase inhibitors.
    Fardis M; Jin H; Jabri S; Cai RZ; Mish M; Tsiang M; Kim CU
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4031-5. PubMed ID: 16716589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching between raltegravir resistance pathways analyzed by deep sequencing.
    Mukherjee R; Jensen ST; Male F; Bittinger K; Hodinka RL; Miller MD; Bushman FD
    AIDS; 2011 Oct; 25(16):1951-9. PubMed ID: 21832937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.